Skip to main content

PHIBRO ANIMAL HEALTH CORP

For the period ended Dec 31, 2023. Filed Feb 7, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2023 · Filed Feb 7, 2024

PAHC$34.64+0.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated Statements of Cash Flows

​​​​​​​​
​ · ​ · Six Months · ​
For the Periods Ended December 31 · 2023 · 2022 · ​
​ · ​ · (unaudited) · ​
​ · ​ · (in thousands) · ​
OPERATING ACTIVITIES · ​ · ​ · ​
Net income (loss)​$(6,741)​$11,066​
Adjustments to reconcile net income (loss) to​​​​​
net cash provided (used) by operating activities:​​​​​
Depreciation and amortization​17,781​16,949​
Amortization of debt issuance costs​520​326​
Deferred income taxes​(6,506)​(121)​
Foreign currency losses (gains), net​2,355​(875)​
Acquisition-related cost of goods sold​​310​​—​
Pension settlement cost​​10,674​​—​
Brazil employment taxes​​4,202​​—​
Stock-based compensation​​161​​—​
Other​2,513​(702)​
Changes in operating assets and liabilities, net of business acquisition:​​​​​
Accounts receivable, net​14,316​14,839​
Inventories, net​(7,546)​(29,082)​
Other current assets​1,934​(7,744)​
Other assets​(134)​1,035​
Accounts payable​11,543​(14,614)​
Accrued expenses and other liabilities​2,375​(4,264)​
Net cash provided (used) by operating activities​47,757​(13,187)​
INVESTING ACTIVITIES​​​
Purchases of short-term investments​(59,523)​(10,000)​
Maturities of short-term investments​40,00017,000​
Capital expenditures​​(18,435)(32,995)​
Business acquisition, net of cash acquired​​(3,326)​​—​
Other, net​1,071​36​
Net cash used by investing activities​(40,213)​(25,959)​
FINANCING ACTIVITIES​​​​​
Revolving credit facility borrowings​93,000​197,000​
Revolving credit facility repayments​(83,000)​(158,000)​
Proceeds from long-term debt​​—​​12,000​
Payments of long-term debt​(10,210)​(7,605)​
Debt issuance costs​​—​​(640)​
Payments of insurance premium financing​​(3,478)​​—​
Dividends paid​(9,721)​(9,720)​
Net cash (used) provided by financing activities​(13,409)​33,035​
Effect of exchange rate changes on cash​(2,446)​285​
Net decrease in cash and cash equivalents​(8,311)​(5,826)​
Cash and cash equivalents at beginning of period​41,281​74,248​
Cash and cash equivalents at end of period​$32,970​$68,422​

PHIBRO ANIMAL HEALTH CORPORATION AND SUBSIDIARIES

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.